InBody Co.Ltd (041830) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of InBody Co.Ltd KRW 58,520, price KRW 53,200, upside +10.0%, quality 71 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch InBody Co.Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 16,777 KRW – 70,800 KRW · fair‑value band 36,989 KRW – 80,812 KRW · the 53,200 KRW price screens below the 58,520 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow InBody Co.Ltd in your weekly email
Every Wednesday you see whether InBody Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
InBody Co.,Ltd provides body composition analysis solutions worldwide. The company offers body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, as well as InBody dial and bands. Its products are used in nephrology, liver disease, diabetes, nutrition, and rehabilitation applications.
Show more
InBody Co.,Ltd provides body composition analysis solutions worldwide. The company offers body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, as well as InBody dial and bands. Its products are used in nephrology, liver disease, diabetes, nutrition, and rehabilitation applications. The company was formerly known as Biospace Co., Ltd. InBody Co.,Ltd was founded in 1996 and is headquartered in Seoul, South Korea.
Stock analysis
InBody Co.Ltd (041830) currently trades at 53,200 KRW, while our model-based Fair Value estimate is 58,520 KRW, implying the stock looks roughly 9.1% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 53,508 KRW per share, and 6 of the 24 models we run sit above the 53,200 KRW price.
Bear case: the Asset-Based group reads lowest at 15,795 KRW, and 18 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: 36,989 KRW (bear) to 80,812 KRW (bull), the price of 53,200 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
InBody Co.Ltd reported revenue of 234B KRW in FY2025 versus 138B KRW in FY2021, a compound +14.1%/yr. Reported net income was 30.6B KRW in FY2025, compounding −2.6%/yr from FY2021.
Key figures
Market cap 723B KRW (≈ $532M) · P/S ratio 4.67 · Dividend yield 1.8% · Net margin 13.1% · Return on equity 1,191% · Return on assets (EBIT) 14.1% · Operating margin 24.5% · Revenue (TTM) 155B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).
What moves the price
The share trades about 25% below its 52-week high and 102% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at 10%, 041830 screens cheaper than that median.
Fair Value models
Bear 36,989 KRWFair Value 58,520 KRWBull 80,812 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+14.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.9%
Start year 2020 (pandemic). Over 10 years: +13.0% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+12.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+10.3%
Dividend (yield on the price)1.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.10% vs 7%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 16%
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +9.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Equipment & Supplies” was too small, so the broader sector is used.)Health Care · 2626 stocks
Beats the sector median on 9/9 measures
Overall it ranks above its sector peers.
Valuation
Quality Score71 · Top 25%
Fair Value upside+10% · Above median
Profitability
Return on assets11% · Top 25%
Net margin (TTM)24% · Top 25%
Operating margin (TTM)24% · Top 25%
Growth and dividend
Revenue growth18% · Above median
Dividend yield (TTM)1.8% · Above median
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Health Care median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "InBody Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/041830
Frequently asked questions
Is InBody Co.Ltd (041830) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 58,520 KRW versus a price of 53,200 KRW, about +10% upside (undervalued).
What is the fair value of 041830?
Our model-based fair value for InBody Co.Ltd is 58,520 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 53,200 KRW.
What is the quality score of 041830?
InBody Co.Ltd has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for InBody Co.Ltd (041830)?
Our model-based price target is the fair value of 58,520 KRW (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 36,989 KRW, optimistic scenario 80,812 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the InBody Co.Ltd stock forecast for 2026?
Our models put fair value at 58,520 KRW, about +10% upside versus a price of 53,200 KRW (undervalued). Cautious scenario 36,989 KRW, optimistic scenario 80,812 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of InBody Co.Ltd (041830)?
InBody Co.Ltd reported trailing-twelve-month revenue of about 155B KRW (latest available figure, as of Sep 24, 2026).
Does InBody Co.Ltd pay a dividend?
InBody Co.Ltd currently shows a dividend yield of about 1.81% relative to its recent price (as of Sep 24, 2026).
What growth is priced into InBody Co.Ltd (041830)?
For today's price to be fair in a discounted-cash-flow model, InBody Co.Ltd would have to grow free cash flow by +11.4 % per year for five years (discount rate 10.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +16.9 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 041830 use?
Our models discount InBody Co.Ltd at 10.7 %: a base by market capitalisation (small), damped by beta 0.69, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For InBody Co.Ltd that is +11.4 % per year a year over ten years, using the same discount rate (10.7 %) and the same formula as our fair value.
How much growth has InBody Co.Ltd (041830) delivered so far?
Over the past 5 years revenue at InBody Co.Ltd grew +16.9 % a year. The price currently implies +11.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of InBody Co.Ltd (041830) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into InBody Co.Ltd (+11.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of InBody Co.Ltd (041830)?
The free-cash-flow yield on the price is 4.37 %: that much free cash flow InBody Co.Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of InBody Co.Ltd (041830)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For InBody Co.Ltd it is 58,520 KRW per share (as of Sep 24, 2026), against a price of 53,200 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is InBody Co.Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 041830 trades below its calculated fair value: price 53,200 KRW, fair value 58,520 KRW, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 041830?
No. The price is what the market pays today (53,200 KRW); the fair value is what the company's own numbers justify (58,520 KRW). For InBody Co.Ltd the two are 5,320 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is InBody Co.Ltd worth?
The market values InBody Co.Ltd at about 723B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 53,200 KRW; our models calculate a fair value of 58,520 KRW per share.
What do the bullish and bearish scenarios say about 041830?
Our models span a range for InBody Co.Ltd: cautious scenario 36,989 KRW, base 58,520 KRW, optimistic 80,812 KRW per share (as of Sep 24, 2026, price 53,200 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of InBody Co.Ltd (041830)?
Balance-sheet figures for InBody Co.Ltd (as of Sep 24, 2026): debt of 0.01 per unit of equity. They feed the Quality Score of 71/100, which measures business quality independently of the share price.
How far is 041830 from its 52-week high?
InBody Co.Ltd trades at 53,200 KRW, about 25% below its 52-week high of 70,800 KRW and 102% above the low of 26,390 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 58,520 KRW is for.
Which stocks are comparable to InBody Co.Ltd?
From the same area (Healthcare) we also value Value Added Technology Co, Mediana Co, Meta Biomed Co, Sewoon Medical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is InBody Co.Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 53,200 KRW, calculated fair value 58,520 KRW (+10%), Quality Score 71/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 041830 calculated?
We run InBody Co.Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 58,520 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. InBody Co.Ltd currently trades 10 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of InBody Co.Ltd (041830)?
The closing price on Sep 23, 2026 was 53,200 KRW. Our model-based fair value is 58,520 KRW, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with InBody Co.Ltd right now?
A fairly wide model range (36,989 KRW to 80,812 KRW) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of InBody Co.Ltd
How large is the market capitalisation of InBody Co.Ltd (041830)?
The market capitalisation of InBody Co.Ltd is 723B KRW (≈ $532M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of InBody Co.Ltd (041830)?
The price-to-sales ratio of InBody Co.Ltd is 4.67 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of InBody Co.Ltd (041830)?
The dividend yield of InBody Co.Ltd is 1.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of InBody Co.Ltd (041830)?
The net margin of InBody Co.Ltd is 13.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of InBody Co.Ltd (041830)?
The return on equity (ROE) of InBody Co.Ltd is 1,191% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of InBody Co.Ltd (041830)?
On an EBIT basis the return on assets of InBody Co.Ltd is 14.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of InBody Co.Ltd (041830)?
The operating margin of InBody Co.Ltd is 24.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at InBody Co.Ltd (041830)?
Revenue at InBody Co.Ltd is growing +17.7% versus a year earlier (3y avg +13.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at InBody Co.Ltd (041830)?
Earnings per share at InBody Co.Ltd are growing +30.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch InBody Co.Ltd in the live analysis
One click puts InBody Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
